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In this review, several aspects surrounding the choice of a therapeutic intervention 
and the conduct of clinical trials are discussed. Some of the background for why 
human studies have evolved to their current state is also included. Specifically, the 
following questions have been addressed: 1) What criteria should be used to deter-
mine whether a scientific discovery or invention is worthy of translation to human 
application? 2) What recent scientific advance warrants a deeper understanding of 
clinical trials by everyone? 3) What are the different types and phases of a clinical 
trial? 4) What characteristics of a human disorder should be noted, tracked, or 
stratified for a clinical trial and what inclusion /exclusion criteria are important to 
enrolling appropriate trial subjects? 5) What are the different study designs that 
can be used in a clinical trial program? 6) What confounding factors can alter the 
accurate interpretation of clinical trial outcomes? 7) What are the success rates of 
clinical trials and what can we learn from previous clinical trials? 8) What are the 
essential principles for the conduct of valid clinical trials?
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INTRODUCTION
“Tilting at windmills” is an old English expression, which means attacking imagi-
nary enemies, fighting unwinnable or futile battles. The phrase is derived from a 
passage from the Spanish novel of Miguel de Cervantes, entitled Don Quixote, 
which was written in 1605. In Chapter VIII of Part 1, Don Quixote wishes to fight 
windmills that he imagines to be giants, much to the bewilderment of his faithful 
and more grounded companion, Sancho Panza (Fig. 1). The word “tilt” here means 
to fight or joust. Today, the phrase is sometimes used to describe a delusional activity 
where the goal (prize or adversary) is incorrectly perceived or emotionally ideal-
ized. In literature the protagonist’s foolish course of action is a misguided effort to 
attain the prize at all cost. A comprehensive review of clinical trials could also be in-
terpreted as ‘tilting at windmills’ as the topic is very complex; we are not delusional 
enough to think we can provide any more than a sketch of such a substantial subject. 
When evaluating our scientific and clinical trial data, we have to ask ourselves 
as researchers whether we sometimes act emotionally and irrationally, like Don John D. Steeves, et al.
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be prevented and treated by supplementing the diet with cit-
rus fruit such as limes or lemons, but not by other acids.1 Par-
enthetically, this early clinical trial was conducted on board a 
ship where scurvy had taken hold of many of the crew.
Thus, valid clinical trial protocols have been around for a 
long time and can be conducted in even the most inhospita-
ble circumstances. Therefore, it is probably not asking too 
much of anyone in the 21st century to adopt the fundamental 
precepts for the design of an objective clinical trial, as well as 
all data being analyzed in a valid and unbiased manner. This 
is easier said than done and a number of inadvertent mistakes 
can result without some initial guidance as to the best way to 
navigate what can be a tortuous trail. What follows is a very 
brief review of some of the central issues associated with 
clinical trials. Our review is populated with examples from 
a number of disorders, although illustrations from spinal 
cord injury (our field of interest) predominate, as it is only 
within this field that we can be confident that the chosen 
example is representative of a more universal issue. 
But probably the first question to tackle is the actual need 
for undertaking a clinical trial in the first place. It is not un-
usual to hear that a good observational study, case report, or 
“open-label” trial can be just as valuable as a rigorous ran-
domized controlled trial (RCT). Perhaps this is true, but a 
couple of difficult criteria have to be satisfied for this ap-
proach to be accepted. First, the outcome of the experimen-
tal therapy has to be strongly “face evident” (i.e. extremely 
obvious), such as the use of parachutes when jumping from 
high altitudes.2 It is true that no one has conducted an RCT 
on the use of parachutes to avoid the consequences of grav-
ity, however several controlled comparison studies have 
been subsequently undertaken to determine the best design 
of later parachutes. Second, the assignment of subjects to 
different groups within an observational study, the observa-
tion of outcomes, as well as any data analysis, must be free 
of even unintended bias by the clinicians. This is unlikely to 
be the case as clinicians are human and subject to unintend-
ed bias like everyone else (see above).
Thus the strongest level of clinical evidence is from mul-
ticenter, double-blind RCTs. An RCT is considered the 
most reliable evidence because the protocols used during 
the conduct of an RCT minimize the risk of confounding 
factors influencing the results (including investigator bias 
or a subject’s expectation). As a result, the findings generat-
ed by RCTs are likely to be closer to the true effect than the 
findings generated by other research methods, including 
observational studies or clinical case reports.3 Nevertheless, 
Quixote, or do we take a more skeptical approach, like San-
cho Panza. How do we guard against our intrinsic emotion 
blinding us to the logical and objective evaluation of a scien-
tific discovery as a treatment for a human disorder? First, ev-
ery scientist and clinician must accept that they are biased 
about their research, which is why regulatory guidelines have 
been established for the valid conduct of human studies in-
vestigating novel therapeutic interventions. No matter how 
passionately we pursue a goal or persistently try to persuade 
our colleagues that our intervention is the best treatment, the 
final determination of its value is in the hands of others. If 
the data is incomplete or the study is experimentally flawed, 
we will end up looking like Don Quixote tilting at windmills!
Clinical trial guidelines are not new; they have been with 
us in various forms since the advent of the written word. 
Some of the best records come from Ibn Sīnā (Avicenna) 
who was a famous Persian physician and philosopher. At 
the height of the Islamic Golden Age, in 1025, he included 
a detailed set of guidelines for the testing of drugs in his 
book, The Canon of Medicine. This work was subsequently 
translated into Latin and still being used as a textbook in 
European medical schools, 600 hundred years later. One of 
the earliest documented clinical trials was that of James Lind 
in 1747 where he used clinical comparisons between exper-
imental and control substances to show that scurvy could 
Fig. 1. Copy of the Pablo Picasso sketch of Don Quixote (1955), copyright 
holder unknown, but presumed to be copyrighted. First appeared in August 
18-24 issue of the French weekly journal Les Lettres Françaises in celebra-
tion of 350th anniversary of the first part of Cervantes’ novel Don Quixote. 
Used here in a completely non-profit and non-commercial manner for schol-
arly research and teaching purposes, under “fair use or fair dealing” exemp-
tions.Tilting at Clinical Trials
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clinical translation process would include independent repli-
cation of promising preclinical strategies.4,5 Furthermore, in-
dependent replication efforts might involve the use of slightly 
different preclinical models (e.g., different severities of the 
disorder) or variations of the treatment paradigm. This would 
establish both the relevance and robustness of the initial dis-
covery. In addition, finding similar beneficial outcomes of 
the experimental intervention in different animal species 
would demonstrate the fundamental nature of the therapeutic 
target and increase the likelihood that the treatment would 
also benefit humans. Finally, all to often, scientists determine 
an intervention has benefit when it is administered immedi-
ately after experimentally creating the disorder in the preclin-
ical animal model (e.g., ischemic stroke). Unfortunately, pa-
tients can rarely be treated within minutes of a sudden trauma 
or illness. Thus, if a therapy purports to be a useful acute 
treatment, it should be demonstrated to have benefit in ani-
mals when administered within a clinically relevant time 
frame (e.g., several hours after the appearance of any acute 
symptoms). If an intervention is suggested to benefit people 
living with a chronic condition, then it should be shown to be 
effective in a chronic animal model.6
As outlined in Table 1, there are several important traits 
of an experimental treatment that must be established prior to 
there are instances when conducting an RCT may be uneth-
ical or virtually impossible, such as the case for many surgi-
cal interventions and then observational studies might be 
the only available approach, but these studies should still 
rely on blinded assessors for the measurement of outcomes 
and data analysis.
WHAT CRITERIA SHOULD BE USED TO 
DETERMINE WHETHER A SCIENTIFIC 
DISCOVERY OR INVENTION IS 
WORTHY OF TRANSLATION TO 
HUMAN APPLICATION?
Clinical trials are expensive, but more importantly no one 
wishes to waste patient resources on a scientific discovery 
that has little or no legitimacy going forward to human ap-
plication. Thus, to generate greater confidence within the 
research community, preclinical research programs need to 
validate their discoveries through the use of high quality 
preclinical protocols that incorporate blinded assessments, 
adequate power, and “functional” outcome measures simi-
lar to those used in a human study. 
Similarly, most scientists would agree that the optimal pre-
Table 1. Characterization of an Experimental Treatment Using Animal Models Prior to Human Study is Necessary and In-
cludes Traits that Often form an Iterative Cycle of (Bench-Bedside-Bench-etc.) for the Ongoing Development of Therapies 
Therapeutic trait Approach Outcome
Temporal “window of 
  opportunity”
Test different time limits for provision of therapeutic 
  strategy after experimentally creating disorder in animal   
  model
Determine early and late time points 
  for the therapeutic having a benefit 
  in animal model
Formulation Examine different: forms of drug, types of cells, 
  or rehabilitation training programs
Identify which formulation provides best 
  actions with minimal adverse effects
Route of administration Investigate what is the most effective route to achieve 
  therapeutic benefit (e.g., intravenous, intraparenchymal)
Determine best potential route for 
  administering intervention to a human 
  subject
Dose
Test different levels (dose response) of therapeutic 
  (e.g., drug doses, cells numbers, or length and number 
  of rehabilitation sessions)
  (also see adverse effects)
Define the optimal dose that will 
  potentially achieve a meaningful benefit, 
  without unwanted side effects or adverse 
  events
Adverse effects Determine doses that cause unwanted side effects 
  or adverse events
Identify tolerable and maximal doses of 
  therapeutic
Fate of drug, transplanted     
  cells, or rehabilitation 
  strategy
Drugs- pharmacodynamics (action of drug on body) and 
  pharmacokinetics (actions of body on drug) absorption, 
  diffusion, metabolism, excretion
Cells- integration with host tissue, distribution, survival, 
  tumorigenicity
Rehabilitation- discover persistence of rehabilitation 
  benefit
Outline the expected duration (length) of 
  benefit that may be achieved through the 
  administration of the therapy
Obtain a better understanding of how the 
  body interacts with the therapeutic inter
  vention
Mechanism of action Identify target or biological action of the intervention 
  (e.g., altered biochemical pathway)
Provides information for development of 
  subsequent (next generation) therapeutics
Rehabilitation strategies (activity-dependent training programs) should undergo similar characterization. John D. Steeves, et al.
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matic cells could be induced to become a variety of plurip-
otent stem and progenitor cells.7-9 After transplantation of 
these pluripotent cells, it is hypothesized that they can dif-
ferentiate into a number of adult cell phenotypes. This prom-
ises an infinite source of cells to repair damaged tissues and 
organs. However, except for some hematopoietic disorders 
or the repair of damaged bone, a great deal of basic science 
still needs to be completed on the control of differentiation 
and transplant survival before these technologies become 
realistic clinical treatment options.
The public media reports for the potential wonders of cell 
transplants have captivated worldwide interest and generat-
ed emotion and hope in people living with a chronic physi-
cal disability. With increased access to scientific and medi-
cal information via the Internet, patients are now very well 
informed. Consequently, all scientists and clinicians need to 
answer a wider scope of questions, ranging from fundamen-
tal cell biology to the many claims for clinical benefits from 
a seemingly endless number of treatment options. In brief, 
all biomedical researchers and health care professionals 
must now be competent knowledge translators. This means 
scientists and clinicians must be able to critically evaluate 
the quality and strength of evidence provided by different 
types of preclinical discoveries and human studies, as well 
as their realistic prospect for clinical application.
Development of the basic cell culture technologies re-
quired for cell transplants is relatively inexpensive and in-
volves only modest biological science expertise. Thus, there 
has been a rapid expansion of independent “for-profit” clin-
ics offering such treatments. The attractiveness of these trans-
plantation practices has understandable appeal to desperate 
patients when presented as a “cure”, but the suppliers are 
currently exploiting their hopes for financial reward. The 
beginning a human study. Satisfying these requirements is of-
ten perceived as scientifically uninteresting, but without rea-
sonable answers for these characteristics, it is doubtful that 
any regulatory agency or institutional review board of a hospi-
tal or university would consider a human study as safe or ade-
quately justified. To assure objectivity and provide confidence 
to trial investors, many of these therapeutic traits are often 
tested by an independent contract research organization. 
Nevertheless, some experimental interventions enter into 
clinical trials without being directly studied in a preclinical 
animal model of the human disorder. This may occur, for 
example, if the treatment has a history for clinical use to treat 
a different disorder, but involves a related therapeutic tar-
get. The advantages for such a translational path include a 
prior understanding of the safety and toxicology of the treat-
ment in humans. Thus when translated to the new disorder, 
there is reduced risk that the intervention might result in 
any adverse events or detrimental side effects (Fig. 2). Nev-
ertheless, off-label prescriptions must serve patient needs 
better than conventional alternatives and must be supported 
by human study evidence for the “new” clinical disorder 
(i.e., a separate clinical trial).
WHAT RECENT SCIENTIFIC ADVANCE 
WARRANTS A DEEPER 
UNDERSTANDING OF CLINICAL 
TRIALS BY EVERYONE?
The biomedical world changed dramatically with the con-
firmation that stem and progenitor cells can be found within 
all adult body tissues, including the brain and spinal cord. 
Furthermore, it was discovered that many adult human so-
Fig. 2. Summary chart of a translational path for a therapeutic intervention from scientific discovery to approval for clinical use.
Functional benefit in animal model
Animal safety
Yes
Yes
No
Phase 1 ʻsafetyʼ trial Safe for this clinical disorder?
Yes No
Phase 2 ʻexploratoryʼ trial Exhibit preliminary functional activity?
Yes No
Phase 3 ʻpivotalʼ trial Provide clinically meaningful benefit?
Yes No
Approved for clinical practice, based on objective valldated evldence
Practice-based evidence/
Related medical target
Observations/Case studies
Proven safe and effective  
for other clinical target
Good idea?
No
Regulatory approvalTilting at Clinical Trials
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not been uniform across the globe. To provide some objec-
tive assistance to what is a complex series of decisions 
weighing the possible risks and benefits for a human study, 
a number of clinical trial guidelines have been created for a 
number of disorders and published by international panels 
of scientists and clinicians, including CONsolidated Stan-
dards Of Reporting Trials (CONSORT). The CONSORT 
Statement is an evidence-based, minimum set of recom-
mendations for reporting RCTs. It offers a standard way for 
authors to prepare reports of trial findings, facilitating their 
complete and transparent reporting, and aiding their critical 
appraisal and interpretation. The CONSORT Statement 
comprises a 25-item checklist and a flow diagram, along 
with some brief descriptive text. The checklist items focus 
on reporting how the trial was designed, analyzed, and in-
terpreted; the flow diagram displays the progress of all par-
ticipants through the trial (all information is freely available 
for download: www.consort-statement.org/consort-state-
ment).
As but one example of the breadth and depth of trial guide-
lines, recent publications have outlined the requirements for 
clinical trials involving subjects with spinal cord injury 
(SCI).11-14 The issues being considered ranged from: 1) the 
degree of spontaneous recovery after SCI, which is neces-
claims of beneficial outcomes are almost always unsubstan-
tiated (i.e. not validated by an objective clinical trial) and 
often rely on anecdotal testimonials from hopeful patients 
or biased practitioners who stand to personally profit. 
At this time, cell transplants are not without risk. There is 
not sufficient knowledge about the means to manage the 
possible fates of most cells after transplantation. Will some 
transplanted cells undertake uncontrolled differentiation and 
form cancerous tumors? Thus, a detailed scientific under-
standing of the potential risks and limited evidence for pos-
sible benefits should be completed prior to providing in-
formed consent for a cell transplant procedure.10 In addition, 
subjects are sometimes reluctant to enroll in an RCT as 
they do not want to find out after the trial that they were 
part of the control group. It is important to emphasize that 
any participant within the control group is receiving the 
current standard of clinical care (i.e., best practices) and 
should the experimental treatment have deleterious effects, 
it is better to have been a control participant (Box 1).
Most countries in the developed world have regulatory 
agencies with established criteria for the safe and effective 
evauation of an experimental therapeutic within a valid 
clinical trial program. Unfortunately, regulatory require-
ments are only as good as their enforcement and this has 
Box 1- TGN1412: How NOT to start a phase 1 (safety) clinical trial
TGN1412 is the working name of a humanized monoclonal anti-
body, which was developed by TeGenero Immuno Therapeutics, 
tested by Parexel and manufactured by Boehringer-Ingelheim. 
TGN1412 was predicted to activate T cells. In its first human 
phase 1 clinical trials in March 2006, it caused severe inflammato-
ry reactions and catastrophic systemic organ failure in all of the 6 
healthy subjects who received the humanized monoclonal anti-
body, despite a supposed sub-clinical dose of 0.1 mg per kg; some 
500 times lower than the dose found safe in animals, including non-human primates. 
The antibody was given by intravenous infusion with an interval of around 10 minutes between patients. 
Thus all 6 subjects received the experimental antibody within one hour. A more conventional phase 1 study 
protocol examines the response in one individual at a time for a sufficiently appropriate period to assure there 
are no adverse events before administering the therapeutic to the second subject. If Parexel had undertaken 
this approach, only one volunteer subject would have suffered. Although the differences between the preclin-
ical animal responses and the human reaction have not been completely explained, it would seem that there 
are some subtle, but significant differences between the pathways for activating T cells in non-human pri-
mates and humans which are beyond the scope of this review. TeGenero has ceased business and, 5 years lat-
er, all human monoclonal antibody clinical trials are still banned in the UK.John D. Steeves, et al.
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monitored throughout all subsequent trial phases. The over-
all translational path for an experimental intervention through 
the various stages of preclinical and clinical study might be 
summarized as shown in Fig. 2. 
Phase 1
Trials are centered on the initial exploration of safety, and 
in the case of a drug, or cell transplant often include an 
evaluation of the responses to different therapeutic doses. 
Moreover, in the case of a drug, the purpose of this phase is 
to characterize its pharmacokinetic behavior and determine 
the metabolic profile. Typically, this is described using the 
acronym, ‘ADME’ which stands for ‘Absorption, Distribu-
tion, Metabolism and Excretion. The primary goal of a 
Phase 1 program is to determine if a projected therapeutic 
blood level, based on preclinical data, can be reached with-
out evidence of harmful side effects in the healthy human 
or targeted population (elderly, pediatric, renal failure, etc.). 
Phase 1 trials will sometimes attempt to collect pilot data 
on functional outcomes, primarily to justify continuation, 
particularly funding, for the trial program. 
Phase 2 
Trials are still exploratory with a focus on the preliminary 
demonstration of functional biological activity and/or func-
tional benefit of the intervention. They will usually com-
pare a number of different biological, clinical or functional 
outcomes to determine which endpoint most reliably mea-
sures a clinically meaningful outcome in a sensitive and ac-
curate manner. Moreover, these studies reveal information 
on the therapeutic response variability seen with a given 
measurement and therefore, provide a basis to calculate the 
study size needed to perform a definitive (Phase 3) study in 
a larger population. In addition, for drug trials, an attempt is 
often made to correlate a given blood level with a therapeu-
tic outcome by dose-ranging studies where the lowest dose 
projected to have efficacy is tested and doses are increased 
in subsequent cohorts to find the best balance between ben-
efit and risk. 
Phase 3
Trials are the pivotal confirmatory studies where an inter-
vention must demonstrate benefit in a clinically meaningful 
manner. This efficacy is then weighed against the associat-
ed risks before the relevant regulatory body can approve it. 
A clinical meaningful benefit for a therapeutic can be diffi-
cult to define (see below), especially for disorders with low 
sary to set reasonable clinical endpoint thresholds,11,15,16 2) 
approaches for selecting accurate, sensitive and reliable 
outcome measures,12,15 3) discussion of numerous inclusion/
exclusion criteria and important ethical considerations,13 as 
well as 4) various trial designs and protocols.14 In addition, 
the same authors created a document written for the general 
public and allied health care professionals, which outlined 
what a patient should ask of any investigator before accept-
ing an experimental intervention, such as a cell transplant 
(available at www.icord.org). 
WHAT ARE THE DIFFERENT TYPES 
AND PHASES OF A CLINICAL TRIAL?
A detailed understanding and appreciation of the clinical 
trial process can be obtained from various national and in-
ternational regulatory agencies such as www.clinicaltrials.
gov. There are a number of different types of clinical trials 
and each has a distinct goal.
1) Diagnostic trials are conducted to find better tests for 
diagnosing a particular disease or disorder and are usually 
conducted with people showing symptoms of that condi-
tion. For example, if researchers wanted to compare the di-
agnostic performance of magnetic resonance spectroscopy     
to that of magnetic resonance imaging (MRI) for a particu-
lar disease, they would conduct a diagnostic trial.
2) Screening trials test the best way to detect certain dis-
eases or health conditions. A screening trial may comple-
ment or overlap with a diagnostic trial.
3) Prevention trials look for ways to prevent illness or in-
jury in people who have never had the disease and the ap-
proaches may include: vaccines, vitamins, exercise, or life-
style changes.
4) Quality of Life trials explore ways to improve access, 
opportunity and integration within the community for indi-
viduals with a chronic illness or disability.
5) Treatment trials are the most familiar and test experi-
mental interventions designed to improve outcomes for pa-
tients whether the therapeutic is a drug, cell transplant, surgi-
cal procedure, assistive device, or rehabilitation strategy. 
However, this does not imply that all these different treatment 
categories have identical regulatory demands for approval. 
Each phase of a clinical trial program also has distinct 
goals and thus different parameters, protocols, outcome mea-
sures, and endpoints that can govern the conduct for each 
stage of investigation. Nevertheless, safety is continuously Tilting at Clinical Trials
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be heterogeneous in terms of:
-Level of injury along the rostrocaudal length of the cord 
(from ventilator-dependent, high cervical SCI to ambulato-
ry, cauda equina injury) 
-Severity of injury (from incomplete spinal damage to 
complete sensory and motor loss below the level of injury)
-Progress since the onset of sensory and motor disrup-
tion, including the degree of ongoing deterioration or spon-
taneous recovery from the acute stage, through sub-acute, to 
more chronic time points.
Therefore, when initially examining an experimental in-
tervention it is prudent to recruit subjects that best approxi-
mate the type of disorder that was created in the preclinical 
studies. In short, it is wise to minimize the variability be-
tween study subjects. If we use SCI as an example, it is pos-
sible to enroll subjects that range from complete sensorimo-
tor loss to a minimal loss of sensory and motor function. 
However, it would be no surprise that people with less se-
vere forms of SCI are capable of more spontaneous recov-
ery than those individuals with complete sensorimotor loss. 
Thus, the potentially different outcomes from heteroge-
neous subjects during a clinical trial may obscure, offset, or 
cancel out detection of any treatment effect for the thera-
peutic intervention. Consequently, the investigators might 
conclude erroneously that there is no treatment effect. A ro-
bust, sensitive and accurate classification system for inclu-
sion and exclusion from a trial is important to enrolling ap-
propriate study subjects.
The greater the variation in the subjects that are recruited 
to a study, the higher the requirement for stratification and 
thus, the lower the statistical power (significance) of any 
analyses. The only way to overcome subject heterogeneity is 
to increase the number of enrolled participants or start again; 
either choice will mean more time and money. For the same 
reasons, it follows that in every possible respect, a (placebo) 
control group should be matched to the composition of the 
experimental study group. Once a therapeutic intervention 
has been validated as beneficial for a homogeneous target 
population, there will be ample opportunity (and funding 
available) to subsequently study other forms of the disorder. 
In addition to homogeneity of study subjects, there are 
other criteria for including and excluding the enrollment of 
subjects to a clinical study.13 Needless to say, these criteria 
will vary as a function of the disorder being evaluated; how-
ever, there are some general principles for all clinical stud-
ies. The hypothesized action of the candidate therapy will 
define the time points for its administration and thus influ-
incidence such as SCI or disorders where no therapeutic in-
tervention has been established as the approved standard of 
care (i.e., the ‘gold’ standard). Finally, Phase 3 studies help 
to create a more substantial safety database by providing in-
formation about potential adverse events or side effects in a 
large number of patients.
After regulatory approval and adoption of the interven-
tion as a standard of clinical practice, most interventions 
enter a surveillance period where the greatly increased ex-
posure of a more heterogeneous array of patients to the 
treatment will enable detection of less frequent adverse 
events. At this stage, it is also possible to perform Phase 4 
(post-market) use studies that continue the examination for 
optimal treatment approaches, and safety in a more con-
trolled way, including additional forms of efficacy and in-
teractions with other treatments the patient may also be re-
ceiving (e.g., drugs). 
WHAT CHARACTERISTICS OF A 
HUMAN DISORDER SHOULD BE 
NOTED, TRACKED, OR STRATIFIED 
FOR A CLINICAL TRIAL AND WHAT 
INCLUSION/EXCLUSION CRITERIA 
ARE IMPORTANT TO ENROLLING 
APPROPRIATE TRIAL SUBJECTS?
In the translation from preclinical animal experiments to 
human studies there are a number of considerations to con-
template. Most categories of human disorders are not ho-
mogeneous in their origin, presentation, or course of pro-
gression. Potential human participants in a clinical trial are 
unlikely to be as homogeneous a group as the preclinical 
animals used in an experimental laboratory. Scientists can 
often create a good approximation of a disorder that may 
match the human disorder in several aspects, but it is a rare 
situation where a preclinical animal model can completely 
mimic a human disorder. 
For example, special impact devices have allowed scien-
tists to create a SCI in animal models within the same rela-
tive time frame for most traumatic human spinal injuries 
(<10 msec), but to date, these devices cannot recreate the 
mechanical damage that may simultaneously compress, 
dislocate and distract the spinal cord along 3 different phys-
ical axes. In addition, a human spinal injury can be ac-
quired from a variety of non-traumatic incidents, including: 
infection, vertebral stenosis, or spinal tumors. Even though 
many people think of SCI as relatively homogeneous, it can John D. Steeves, et al.
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ing a smaller sample size. Conversely, it is difficult to bio-
logically influence damaged tissues or cellular actions in a 
positive manner at chronic time points. 
Most clinical trials have lower and upper age limits for 
subject enrollment. Lower limits are often set at the legal 
age for adulthood (often 18 years of age) as this facilitates 
ethical considerations surrounding direct informed consent 
being adequately provided, understood, and agreed to by 
the potential study participant. The upper limit (usually 55-
70) is often influenced by two major considerations. First, 
older study participants may not have the same rate for 
spontaneous recovery and their diminished capacity may 
not align appropriately with younger participants, leading 
to inconsistent trial outcomes. Aging is often accompanied 
by pre-existing or co-existing medical conditions that may 
also influence or alter the outcomes of a clinical trial. The 
longer and more physically active lifespans of many people 
means careful attention must be maintained in matching 
study participants in terms of age and functional capacity. 
There is growing consensus that active physical and oc-
cupational rehabilitation benefits faster and greater recov-
ery after most health challenges. In short, it can be argued 
that rehabilitation training is a necessary component for max-
imizing recovery after any surgical or drug intervention. 
Nevertheless, augmented rehabilitation has its own intrinsic 
benefits and conversely physical inactivity can worsen func-
tional improvement. Thus, when undertaking a clinical trial 
of a therapeutic intervention, it is possible that rehabilitation 
effort can be an independent variable that confounds the ac-
curate determination of how much benefit was due to the 
therapy or to the accompanying rehabilitation. Without 
more rehabilitation RCTs providing the necessary wisdom 
for the “yin and yang” of active physical and occupational 
training, rehabilitation will remain a double-edged sword. 
Nonetheless, it is important to attempt to standardize rehabili-
tation during a clinical trial and at a minimum activity should 
be monitored and tracked over the course of the study. 
Depending on the therapeutic target, gender may or may 
not be a confounding factor during the course of a clinical 
study, but pregnant women or women unwilling to use dou-
ble barrier methods to avoid pregnancy during the course of 
a clinical trial are usually excluded. The known risks for an 
adult drug dose being delivered to an unborn fetus (Box 2)
are the obvious reason and also exclude adolescent children 
from most initial treatment trials. Should a therapeutic be 
approved as a beneficial standard of care, a subsequent trial 
can be initiated for these populations. 
ence which subjects are appropriate to recruit to the study. 
For example, tissue Plasminogen Activator (tPA) is a pro-
tein involved in the breakdown of blood clots. It catalyzes the 
conversion of plasminogen to plasmin, the major protein 
responsible for the breakdown of blood clots. tPA is used to 
treat ischemic stroke within a few hours after the onset of 
stroke symptoms (usually <3-4.5 hours), but contraindicat-
ed in hemorrhagic stroke where it would exacerbate out-
comes. This is a challenging “window of opportunity” for 
the administration of tPA since many patients do not seek 
medical assistance quickly, and/or an MRI cannot be com-
pleted within this time frame to rule out hemorrhagic stroke. 
As a consequence, the majority of people suffering an isch-
emic stroke do not receive tPA. 
The need to rapidly identify and accurately screen suit-
able participants is a major challenge to recruit a sufficient 
number of participants for any acute clinical trial. Regard-
less of the clinical target, the list of inclusion and exclusion 
criteria can quickly reduce the number of qualified subjects 
and it is not unusual to enroll less that 10% of the initially el-
igible participants (Fig. 3). But, should the diagnosis for the 
severity of the disorder be difficult to correctly determine, 
you could enroll an inappropriate participant that will dis-
tort trial outcomes.
The chronic stage of some disorders, such as SCI, yields 
a fairly static functional baseline where there is little ongo-
ing functional improvement beyond the first year after inju-
ry. As a result, some chronic studies have a broader time 
range for the recruitment of subjects with varying survival 
times. The low functional variability in chronic activities of 
daily living facilitates the detection of a treatment effect us-
Fig. 3. The necessary inclusion and exclusion criteria to qualify as a trial 
subject can create a funnel effect that substantially reduces the number of 
trial participants that can enroll in a human study. This can be a very diffi-
cult challenge for rare (small incidence) disorders and to generate suffi-
cient participants may require recruitment from multiple center trials at 
even the earliest phases of a study.
The funnel effect for enrollment of trial subjects
100 subjects
<10 subjects
enrolled
Select examples of 
exclusion criteria:
-No informed consent
-Time since onset 
  of illness
-Co-morbidity
-Prior care/ongoing 
  treatment
-Accuracy of disorder 
  classificationTilting at Clinical Trials
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Pharmaceuticals for Human Use (available at www.ich.
org). In addition, any clinical trial must minimally adhere to 
the ethics guidelines of the Declaration of Helsinki, the Bel-
mont Report, and the standards of the host country (Box 3). 
Where these ethical standards come into conflict, it is the 
responsibility of the investigators to work with review com-
mittees and regulatory agencies to determine whether the 
study can be undertaken or continued.18
Besides the ethical use of study subjects, one of the pri-
mary goals in designing a valid clinical trial program is the 
removal of any bias in the outcomes of the results. Bias is 
defined here as the systematic tendency of any factors asso-
ciated with trial design, conduct, analysis, and interpreta-
tion of results to cause the estimate of a treatment benefit to 
deviate from its true value. It must be remembered that it is 
relatively easy to get positive responses from subjects when 
they know they have recently been treated with an experi-
mental therapy, and when they expect or hope for a benefit 
(the so-called ‘placebo effect’). Thus, trials with random-
ized controls and blinded assessments are necessary stan-
dards to remove investigator and subject bias. Before a 
study commences, all trial protocols should be registered 
with appropriate regulatory agencies where the study is to 
be conducted (e.g. http://prsinfo.clinicaltrials.gov). Need-
less to say all clinical trial results, whether positive or nega-
tive, should be submitted for publication.
There are varying degrees of blinding, starting with ‘Open 
Concomitant medications or treatments can also constitute 
a criterion for exclusion of a subject from a study. Minimally, 
all medications and alternative treatments (e.g. acupuncture, 
herbal medicines) must be documented and tracked over the 
course of a study. Previous participation in a clinical trial 
may also constitute a reason for exclusion as the previous in-
tervention might contaminate the results of the current trial 
(e.g. synergistic or antagonistic therapeutic effects). Prior to 
enrollment, there has to be sufficient evidence that the study 
subject has not retained any residual effects from a previous 
therapeutic intervention. This does not mean that the patient 
cannot receive the treatment once it has completed a clinical 
trial program and been approved for use (as long as the pa-
tient still qualifies for the approved use of the treatment). 
More detailed discussions of subject inclusion/exclusion cri-
teria and ethics can be found elsewhere.13,17
WHAT ARE THE DIFFERENT STUDY 
DESIGNS THAT CAN BE USED IN A 
CLINICAL TRIAL PROGRAM?
Numerous guidelines for the general conduct of any clini-
cal trial have been developed, and readers are encouraged 
to make themselves familiar with these teachings, especial-
ly those developed by the International Conference on Har-
monization of Technical Requirements for Registration of 
Box 2- Thalidomide: Why pregnant women are not enrolled in clinical trial programs
Thalidomide, launched by Grünenthal on 1 October 1957, was 
found to act as an effective tranquilizer and painkiller and was 
also found to be an effective antiemetic, which had an inhibitory 
effect on “morning sickness”. Thousands of pregnant women 
took the drug to relieve their symptoms. At the time of the drug’s 
development it was thought unlikely that any drug could pass 
from the mother across the placental barrier and harm a develop-
ing fetus. Of course, everyone today knows this is not true.  
Thalidomide was sold in a number of countries across the world from 1957 until early 1962. Canada was 
the last of 46 countries to have thalidomide withdrawn from the market after it was found to be a major cause 
of fetal deaths or teratogenic birth defects (especially of the limbs). It is not known exactly how many vic-
tims of the drug there have been, although estimates range up to 20,000. Since then thalidomide has been 
found to be a valuable treatment for a number of medical conditions, including multiple myeloma. Thalido-
mide is being prescribed again in a number of countries, although its use remains controversial as to how to 
protect pregnant women from being administered the drug. John D. Steeves, et al.
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blinding of surgical outcomes to independent examiners. 
Finally, in an optimal ‘Double Blind’ design, neither the 
participating trial subject, or investigators, trial staff, and 
sponsors should be aware of the treatment received by the 
subject. Ideal blinding would ensure that the treatments 
couldn’t be distinguished by subjective experience, appear-
ance, timing, and delivery method by anyone. This should be 
maintained throughout the conduct of the entire trial from de-
termination of eligibility through evaluation of all endpoints, 
and requires full compliance of the subject. Double Blind de-
sign has been used in numerous pivotal Phase 3 trials.
Randomization in the assignment of trial participants to 
the different study arms (groups), including a placebo con-
trol group, is done to reduce bias in the outcomes of a trial. 
This provides a valid statistical basis for the evaluation of 
any treatment effect. External independent randomization 
tends to produce study groups where the distribution of any 
known or unknown independent variables (confounding in-
fluences) are similar and representative of the overall pa-
tient population. Randomization should only be performed 
after the eligibility of the subject to participate in the trial 
Label’, wherein the identity of the treatment is known to 
both the investigators and participants. ‘Open Label’ proto-
cols have been used in the study of both pharmacological, 
surgical and rehabilitation interventions. They should gen-
erally be reserved for Phase 1 trials. 
The next level is a ‘Single Blind’ study where either the 
clinical investigator (examiner) or the subject, but not both, 
are blinded. For trials where a surgical intervention is part 
of the experimental protocol, it may be necessary for the 
surgeon to know what is being undertaken in that subject. 
However, it is preferred that the patient remain blinded to 
the treatment received (for both experimental and control 
groups), although this is not always possible. Ethical or le-
gal difficulties may interfere with the use of blinding when 
it entails sham operative procedures. Nevertheless, inde-
pendent outcome examiners should and can always be used 
and remain blinded to the treatment provided. This may also 
require audio monitoring to assure that a subject does not 
disclose to the examiner which treatment arm they were as-
signed. Using techniques such as identical bandaging of the 
overlying skin during assessments can also facilitate the 
Box 3- Tuskegee syphilis study: An unethical clinical trial that generated new regulations to protect 
human study participants
The Tuskegee syphilis study was an infamous clinical study con-
ducted between 1932 and 1972 in Tuskegee, Alabama by the 
U.S. Public Health Service to study the natural progression of 
untreated syphilis in poor, rural black men who thought they 
were receiving free health care from the U.S. government. Inves-
tigators enrolled in the study a total of 399 impoverished, Afri-
can-American field workers who had previously contracted 
syphilis before the study began. They were never told they had 
syphilis, nor were they ever treated for it. The victims of the study included numerous men who died of 
syphilis, wives who contracted the disease, and children born with congenital syphilis.
The 40-year study was controversial for reasons related to ethical standards; primarily because researchers 
knowingly failed to treat patients appropriately after the 1940s validation of penicillin as an effective cure for 
syphilis. The ethical decision should have been to stop the study and provide all the participants with antibi-
otic treatments. Instead, the Tuskegee scientists continued the study without treating any participants and 
withholding penicillin and information about it from the patients. 
Revelation of this unethical study in 1972 led to an immediate halt of the study and major changes in regula-
tions for the protection of participants in clinical studies. Now studies require detailed informed consent from 
participants before they enroll in a human study. The Tuskegee syphilis study led to the 1979 Belmont Report 
and the establishment of the Office for Human Research Protections (OHRP). It also led to the creation of Insti-
tutional Review Boards (IRBs) for the protection of human subjects in studies involving human subjects.Tilting at Clinical Trials
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be evident within the treatment period, and reverse follow-
ing removal of the treatment. One important concern for a 
crossover design is the possibility of residual effects (i.e., a 
carryover influence) from either the experimental treatment 
or the placebo control. A lingering effect might alter the sub-
ject’s response after crossing over to the opposite treatment 
arm. Thus, the ‘washout’ time period between treatment 
conditions should be sufficiently long to allow the complete 
reversibility of any detectable treatment effect. Nevertheless, 
an advantage of a crossover design is usually a reduction in 
the number of subjects needed to achieve statistical signifi-
cance. Once again, the trial should employ examiners ‘blind-
ed’ to the treatment the subjects are receiving during each 
stage of a crossover study.
An independent Data Safety Monitoring Board or Inde-
pendent Data Monitoring Committee can use a group se-
quential design to facilitate an interim analysis. It involves 
any statistically valid analysis intended to compare treat-
ment arms with respect to safety or efficacy at any time be-
fore the completion of the trial. Such an approach can be 
used to identify and quickly discontinue an unsafe trial, 
stop a trial when the treatment has demonstrated dramatic 
benefit, or identify an ineffective treatment dose with the 
subsequent randomization of subjects to a potentially more 
effective dose. Utilization of such a design requires a decla-
ration, at the beginning of a trial, that an interim analysis 
will be undertaken, and the use of prospectively defined cri-
teria (thresholds) for the early termination due to either 
safety or efficacy reasons.
Factorial Designs involve the testing of two or more treat-
ments simultaneously for possible synergistic or antagonis-
tic effects (combination treatments). In the simplest 2×2 
form, subjects are allocated to one of four groups: A alone, 
B alone, both A and B, or neither A nor B. In ‘Add-on’ Tri-
als, the test treatment and placebo are added to a common 
standard therapy. 
Since there is usually an ongoing debate within any re-
search community over the improved benefits that will be 
achieved with a combination of treatments, it is sometimes 
suggested that a factorial clinical trial does not need to in-
clude separate study groups that individually examine only 
one element of the combination therapy. To undertake this 
expedited approach requires strong preclinical animal data 
that the combination therapy is effective. Alternatively, the 
isolated administration of the individual components in pre-
vious clinical trials may have only demonstrated a modest 
effect that was sub-threshold to achieving any clinically 
has been established. Randomization schemes for multi-
center trials should be centrally organized and ‘blocked’ by 
each participating center, such that all participants within a 
center are also randomized to the different study groups.
There are numerous variations in the design of clinical 
trials, but only the most prevalent trial design configura-
tions are provided below. Parallel group design is the most 
common clinical trial design for pivotal Phase 3 trials. Sub-
jects are randomized (often in equal numbers) to one or more 
treatment arms, each testing a different treatment or combi-
nation of treatments. The treatments might include the in-
vestigational product at one or more doses, and one or more 
control conditions such as a placebo and/or an active com-
parator, which is a current (standard of care) treatment be-
ing provided to both the experimental and control groups. 
There are many variations for a parallel group design in-
cluding superiority or non-inferiority trials. 
As indicated above, superiority trials examine the new 
experimental therapeutic against a comparator, often the 
current standard of treatment, with the intent to show the 
new therapy is better. Often as not, the trial may only dem-
onstrate equivalency or the non-inferiority of the experi-
mental treatment. Then the decision whether to license the 
new treatment is usually determined on other criteria, such 
as less side-effects, lower dose, less cost, longer action, etc.; 
all of which requires additional data. Nevertheless, the as-
sumptions underlying the parallel group design are less 
complex and more robust than those of other designs.
Crossover designs consist of randomly assigning subjects 
to a sequence of two or more treatments (e.g., placebo con-
trol first and then the experimental therapeutic or vice ver-
sa). Hence, the subject acts as his or her own control for the 
evaluation of benefits from the experimental treatment. To 
make valid assessments for the functional efficacy of a treat-
ment using a crossover design, the clinical outcome mea-
sure (primary endpoint) must have a very stable (unchang-
ing) baseline value before application of the experimental 
treatment and any subsequent measurements. Because the 
functional capacities of a person with an acute or sub-acute 
disorder can vary dramatically over a short period of time, 
this type of design should be restricted to studies of chronic 
illness, where the functional capacity to be assessed is ex-
pected to remain stable and unchanging. Thus, a crossover 
trial in patients with a progressively deteriorating disorder 
is not advised unless the rate of deterioration has a longer 
time frame then the therapeutic being tested. 
In addition, the effects of the experimental treatment should John D. Steeves, et al.
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subsequent analysis of their influence on trial outcomes. In 
any case, these decisions should be declared prospectively 
prior to the commencement of the study. 
There are, however, a number of confounding factors that 
any investigator can control so they do not alter the accurate 
interpretation of clinical trial outcomes (Table 2). With the 
use of appropriate study designs and protocols the influence 
of these confounders can be mitigated and/or marginalized. 
One issue that is always a concern is the choice of appro-
priate outcome measures and how often and for how long 
the outcome measures should be assessed. The specific out-
come measures and trial endpoints can and should change 
as the trial program progresses through the various phases. 
The objectives of Phase 1 trials can be quite varied, from the 
initial exploration of tolerability, through study of human 
pharmacokinetics and metabolism, to identification of the 
maximum safely tolerated dose of a candidate therapeu-
tic.12,14 Participant’s who choose to take part in a Phase I tri-
al may experience significant risks with a limited probabili-
ty of receiving individual benefit. 
General Phase 1 trial safety outcome measures include: 
ongoing assessment of standard vital signs, physical exami-
nation data (e.g., temperature, respiration, heart rate, and 
blood pressure), clinical laboratory tests (e.g., hematology 
and urine analysis), as well as the appearance of any system-
ic adverse event (observed or reported by a trial subject). De-
pending on the therapeutic drug or cell line being evaluated 
meaningful benefit. Preclinical safety and toxicity data would 
also be required to indicate that the components of the ther-
apy are safe, when administered separately or when they 
are combined.
WHAT CONFOUNDING FACTORS CAN 
ALTER THE ACCURATE 
INTERPRETATION OF CLINICAL 
TRIAL OUTCOMES?
A list of several potential confounding factors that could 
jeopardize the accurate interpretation of the outcomes in a 
clinical trial is provided in Table 2. Some of these influences 
are unknown and/or beyond the control of the investigators 
conducting the trial. Depending on the start and end dates of 
the trial, subjects may have already been influenced by a va-
riety of emergency, primary care or rehabilitation treatments. 
There may be concomitant damage to a varying number of 
body tissues or cellular functions. For longer-term studies, 
the amount of rehabilitation effort expended by study partici-
pants can be highly divergent. It is unethical to tell a person 
they cannot engage in exercise or active rehabilitation. Thus 
in many instances, the choices are either to provide all sub-
jects with uniform high levels of ongoing care or rehabilita-
tion, which is expensive and sometimes futile. Alternatively, 
any differences can be carefully tracked and documented for 
Table 2. Confounding Factors that Could Alter the Accurate Interpretation of Clinical Trial Outcomes. These Factors May or 
May Not Be Controlled by the Study Investigator, but Should be Carefully Noted Over the Course of the Study and Taken Into 
Consideration during the Analysis of Data
Possible confounding factor(s)
Can this confounder  
always be controlled by 
study investigator (Y/N)
Prior emergency or primary care, intensive care treatment and ongoing patient management N
Surgical procedures not related to therapy (and timing of surgery) N
Damage to other organs or subsequent medical complications after onset of disease or disorder N
Onset, type, and extent of rehabilitation activity in which subject engages during trial N
Unsuitable study protocol design or statistical analysis of trial results Y
Inappropriate inclusion and exclusion criteria for subject to participate in trial (e.g. different: distinct 
  types of disorder, severities of disorder, or time since onset of disorder) Y
Lack of “blinded” randomization of subjects and randomization of the treatment allocation sequence Y
Lack of appropriate control subjects, which match criteria of experimental treatment group Y
Investigator or subject expectations and bias, because they know the type of treatment being provided to 
  the subject Y
Inappropriate, insensitive or unreliable clinical outcome tools and/or primary outcome measure (clinical 
  trial endpoint) Y
Lack of independent “blinded” assessments of trial outcome measures Y
Poor intra- and inter-rater reliability of outcome assessments (lack of ongoing training of trial assessors) Y
Lack of sufficient follow-up assessments (sometimes 6-12 months after trial completion) YTilting at Clinical Trials
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independent therapeutic value that is separate from the drug, 
cells, or device that is implanted. When is the best time to 
make a baseline (starting) outcome assessment, before or 
after the surgical procedure? The most prudent approach 
would be to examine baseline capacities, both before and 
after surgery, to determine if the surgery alone might have 
provided a beneficial outcome. The number of times over 
the course of the study that an interim outcome assessment 
is performed before the endpoint evaluation is dependent on 
the presumed mode of therapeutic action and the duration 
of the study, but is usually no less than 2-3 interim exami-
nations. More frequent assessments may be made at earlier 
study time points, but the number of evaluations depends 
on numerous factors, not the least of which are the de-
mands placed on the subjects and the cost for completing 
each assessment.
Detailed reasoned explanations on specific clinical trial 
procedures and conventions have been written for every 
major clinical disease or disorder (e.g., SCI14) and should 
be reviewed prior to engaging in a clinical trial. It is impor-
tant that all trial investigators understand the reasoning be-
hind the specific trial protocol and agree to abide by the 
guidelines for the study.19 
WHAT ARE THE SUCCESS RATES OF 
CLINICAL TRIALS AND WHAT CAN WE 
LEARN FROM PREVIOUS CLINICAL 
TRIALS? 
A recent Reuters News article from February 14, 2011 
(http://www.reuters.com/article/2011/02/14/us-pharmaceuti-
cals-success-idUSTRE71D2U920110214?pageNumber=2) 
quotes several sources, from 2004 through 2010, that suggest 
the overall success rate for drugs moving from early stage 
Phase 1 clinical trials to FDA approval is about one in 10, 
down from one in five in previous years. BIO and BioMed-
Tracker, which collects data on drugs in development, con-
ducted the study. Some 63 percent of drugs in Phase 1 testing 
did advance to Phase 2, but only 33 percent of Phase 2 drugs 
made it to Phase 3. Approval applications were filed for 55 
percent of the drugs that made it through the completion of 
pivotal Phase 3 study, and 80 percent of those gained eventu-
al approval, although only half were approved after their ini-
tial FDA review. There are a lot of considerations in the deci-
sion to advance to the next phase of a clinical trial program 
and even when the trial data is positive, it does not guarantee 
and the route of administration, other Phase 1 safety outcome 
measures may include the evaluation of unintended effects 
on the target tissue for the therapeutic or other body tissues, 
including infection, inflammation, or immune reactions.
Combined Phase 1/2 trials, where safety and bioactivity of 
the therapeutic are evaluated together can often occur when 
the Phase 1 trial cannot involve healthy subjects and is re-
stricted to people having the clinical disorder. It is possible 
for SCI clinical trials to be designed in this manner. Never-
theless, the data from such a combined Phase 1/2 trial must 
be able to satisfy the essential outcomes for each respective 
trial phase. The preliminary Phase 2 data are collected to de-
velop a preliminary sense of potential efficacy and to assist in 
the identification of appropriate outcome measures to be used 
in subsequent properly powered Phase 2 or 3 trials.
During a Phase 2 study, an exploratory evaluation of effi-
cacy becomes more prominent, with the objective of deter-
mining potential effect size and variability of an experimental 
therapy in comparison to a useful control group. Information 
is gained regarding choice of optimal end points for a larger 
Phase 3 confirmatory trial of efficacy. During a Phase 2 tri-
al, additional information is also obtained regarding safety. 
The preferred Phase 2 design would be a RCT where each 
participant is recruited prospectively and randomly assigned 
to either the experimental or control arm of the study and 
where the investigators and the participants are blinded to 
which study arm they have been assigned. If available, Phase 
2 trials could employ surrogate end points, which are expect-
ed to be accurate predictors of functional improvement, to es-
timate presumed effective doses, and to allow trials of shorter 
duration and smaller size to be conducted. Therapies con-
ceived as early interventions or acute stage treatments are 
likely to be administered within days of the trauma or onset 
of the disorder and it is important that the outcome tools have 
the ability to accurately and sensitively track meaningful 
changes across a broad chronological timeframe.
Phase 3 (therapeutic confirmatory) trials are generally the 
definitive or pivotal clinical trial phase and typically under-
taken as a RCT. The object is to confirm the preliminary 
evidence obtained at the Phase 2 stage by demonstrating a 
statistically significant and clinically meaningful benefit of 
the therapeutic in a wider group of subjects across multiple 
study centers (see below). 
An interesting consideration for Phase 2 and 3 outcome 
measures is the situation where the technique for adminis-
tering the experimental therapeutic intervention, such as 
surgery or a concomitant surgical treatment might have an John D. Steeves, et al.
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many factors, including: 1) the stage of the disorder being 
tested, 2) the magnitude of any spontaneous improvement 
(natural history), 3) the therapeutic target of the intervention, 
4) the primary outcome measure being used in the study, and 
5) the benefits achieved by any previous treatment (i.e. cur-
rent standard of care). Given the potential magnitude of any 
consensus statement about what constitutes a MCID for a 
given clinical trial, most clinical specialties have struggled 
to reach agreement on what is operationally meant by the 
terms “Important” and “Meaningful”. Perhaps it is equally 
important to also consider “for what” benefit and “to whom” 
does it matter. Is this decision the right of patients alone or 
do patients in consultation with the investigators better de-
fine a MCID, as the latter better represents the overall inter-
ests of society?
Recently, the World Health Organization established an 
International Classification of Functioning, disability and 
health (abbreviated as ICF) to better represent the continu-
um of disability domains, including evolving patient goals, 
barriers to patient independence and community participa-
tion, as well as how these issues should best be tracked. ICF 
is a taxonomic structure or bio-psycho-social model inte-
grating medical and social influences on disability (Fig. 4). 
Although many biological and medical investigators focus 
on improving body function after damage, it is not as mean-
ingful to the patient unless the treatment enables a more in-
dependent lifestyle and increases the individual’s commu-
nity participation. Clinically meaningful recovery after a 
disorder or disease benefits from complementary interven-
tions. An improvement in body functions and/or the capaci-
ty for independent activities increases the performance and 
participation of a person within their community.
SUMMARY: WHAT ARE THE ESSENTIAL 
PRINCIPLES FOR THE CONDUCT OF 
VALID CLINICAL TRIALS?
In brief, human studies without appropriate control data 
and blinded assessments are NOT pivotal clinical trials and 
will not validate an intervention as a treatment. Payment 
(by a subject) for an experimental treatment automatically 
means it is NOT a clinical trial, as the investigator has a fi-
nancial incentive (i.e., a bias). It is also more difficult (but 
not impossible) to develop an effective trial design and pro-
tocol for a disorder, which has yet to validate a treatment 
with a clear clinical benefit. In short, it is easier to develop 
advancement through a program. Corporate decisions are 
based on risk-benefit analysis, which may often be the ratio 
of financial benefits to risks and not patient benefits or risks! 
Nevertheless, the wisdom gained from “failed” clinical tri-
al programs can provide valuable information and guidance 
for the next generation of human studies. Thus, the thought-
ful publication of all clinical trial outcomes can always pro-
vide lessons, such as how the next study might conduct their 
trial in a more informed manner (i.e., what to do and what 
not to do). Prior clinical trial data is also valuable for under-
standing the “natural history” of any disorder. Knowledge of 
the biological and functional capacities, limitations or vari-
ability within a population of individuals can establish rea-
sonable clinical outcome (endpoint) thresholds that must be 
exceeded by any experimental therapeutic to demonstrate 
both a statistical and a meaningful benefit in the next trial.11,15 
Previous trial data can also help inform the research com-
munity about what might be a minimal clinically important 
difference (MCID) when conducting a trial for that target 
population. MCID is an important emerging concept that can 
be difficult to define, especially for neurological disorders. In 
brief, MCID is the smallest difference in an outcome mea-
sure that is perceived as beneficial (clinically meaningful) 
and would lead to a change in the patient’s medical manage-
ment or ongoing lifestyle (activities of daily living), assum-
ing an absence of excessive side effects (risks) or costs.20 
In determining a MCID for an outcome measure, several 
ingredients are needed, including: 1) an indicator that a 
change has been facilitated by the experimental therapeutic 
(i.e., a statistical difference exists between the experimental 
and control groups), 2) the observed change has value in 
terms of the patient achieving a functional benefit, 3) an ap-
propriate method to determine the MCID threshold level 
for the outcome measure, and 4) a reasonable percentage 
difference between the experimental and control groups for 
those subjects achieving the MCID outcome threshold (i.e. 
responding). 
For example, it may not be sufficient to demonstrate a 
drug reduces cholesterol level (the surrogate outcome); it 
may be necessary to show that the drug actually reduces the 
incidence of coronary artery disease. In the case of SCI, it 
may not be sufficient to show that a patient has gained some 
motor function from a treatment unless the neurological 
change can be related to an improvement in functional activi-
ties of daily living, such as improved independence for activ-
ities of self-care. It can be readily appreciated that setting a 
MCID for any disorder can be challenging and depend on Tilting at Clinical Trials
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utilizes patients in the most ethical and effective manner. Un-
fortunately, space limitations does not permit discussion of the 
emerging analytic approaches, including Bayesian and Re-
sponder analyses, which may be more suitable to some trials 
than the conventional “comparison of the means” statistics.
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The optimal foundations for an ideal clinical trial program 
are difficult to guarantee, but planning how to achieve some 
of these is instructive. The considerations may include:
-Compelling preclinical data (independently replicated) 
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